Samsung Biologics has submitted a $1.8 billion acquisition bid for PolyPep. The offer was made on July 20, 2026. No further details about the proposed deal have been disclosed.
Samsung Biologics has made a $1.8 billion bid to acquire PolyPep. The offer was announced on July 20, 2026. The bid is valued at $1.8 billion. No additional information about the terms or timeline of the proposed acquisition has been released.
The bid amount is $1.8 billion. Samsung Biologics is the company making this bid. PolyPep is the target of the acquisition. The bid represents an offer to purchase PolyPep at a price of $1.8 billion. The specific reasons for the acquisition and the structure of the offer have not been disclosed.
Samsung Biologics is the bidder in this transaction. The company has placed a $1.8 billion bid to acquire PolyPep. The bid is for the full acquisition of PolyPep. Samsung Biologics has not provided any further commentary or additional details about the bid beyond the amount of $1.8 billion.
PolyPep is the company being acquired under this bid. Samsung Biologics is offering $1.8 billion to purchase PolyPep. PolyPep is the target of the acquisition. The bid of $1.8 billion is directed at acquiring PolyPep. No further information about PolyPep has been included in the announcement of the bid.
The $1.8 billion bid from Samsung Biologics represents a significant offer in the biopharmaceutical sector. The acquisition of PolyPep is valued at $1.8 billion. The bid was made on July 20, 2026. No other details have been provided about the bid or the companies involved. The bid is an offer to purchase PolyPep for $1.8 billion. Samsung Biologics has made this bid to acquire PolyPep.
Related reading: Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion, Samsung Biologics to Buy PolyPeptide in All-Cash Deal, Telehealth Visit Results in Prescription of Unapproved Peptides, Survey Shows Rise in Peptide Misinformation and Misuse in US.